XML 89 R12.htm IDEA: XBRL DOCUMENT v3.25.3
Financial Instruments
 9 Months Ended
Sep. 30, 2025
Investments, All Other Investments [Abstract]  
Financial Instruments

6. Financial Instruments

 

Cash, Cash Equivalents, Restricted Cash and Marketable Securities

 

The following tables show the Company’s cash, cash equivalents, restricted cash, and marketable securities by significant investment category as of:

 

   September 30, 2025 
   cost  

Unrealized

Gain/(Loss)

  

Fair

Value

  

Cash and

Cash

Equivalents

  

 

Marketable

Securities

   Investments 
Cash  $5,785,000   $-   $5,785,000   $5,785,000   $-   $      - 
Restricted Cash   100,000    -    100,000    100,000    -    - 
Level 1                              
Money Market Funds   1,234,000    -    1,234,000    1,234,000    -    - 
Marketable Securities   25,619,000    (15,797,000)  $9,822,000    -    9,822,000    - 
Total  $32,738,000   $(15,797,000)  $16,941,000   $7,119,000   $9,822,000   $    - 

 

   December 31, 2024 
  

Adjusted

Cost

  

Unrealized

Gain/(Loss)

  

Fair

Value

  

Cash and

Cash

Equivalents

  

 

Marketable

Securities

   Investments 
Cash  $11,369,000   $-   $11,369,000   $11,369,000   $-   $- 
Level 1            $-                
Money Market Funds  $62,000    -   $62,000    62,000    -    - 
Marketable Securities  $25,933,000    (16,722,000)  $9,211,000    -    9,211,000    - 
Total  $37,364,000   $(16,722,000)  $20,642,000   $11,431,000   $9,211,000   $       - 

 

The Company typically invests with the primary objective of minimizing the potential risk of principal loss. The Company’s investment policy generally requires securities to be investment grade and limits the amount of credit exposure to any one issuer. Fair values were determined for each individual security in the investment portfolio.